IGF-1R Inhibitor Ameliorates Diabetic Nephropathy with Suppressed HMGN1/TLR4 Pathway

Publisher： Bentham Science Publishers

E-ISSN： 2212-3873|18|3|241-250

ISSN： 1871-5303

Source： Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol.18, Iss.3, 2018-04, pp. : 241-250

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

HMGB1, TLR and RAGE: a functional tripod that leads to diabetic inflammation

By Nogueira-Machado Joséé Augusto   Volpe Caroline Maria de Oliveira   Veloso Clara Araujo   Chaves Miriam Martins  

Expert Opinion on Therapeutic Targets, Vol. 15, Iss. 8, 2011-08 ,pp. : 1023-1035

Informa Healthcare

Access to resources Recommend Favorite

Regulation of IRS-2 signaling by IGF-1 receptor in the diabetic rat heart

By Jiang Youde   Steinle Jena J.  

Canadian Journal of Physiology and Pharmacology, Vol. 88, Iss. 5, 2010-05 ,pp. : 553-561

NRC Research Press

Access to resources Recommend Favorite

Crosstalk between IGF-1R and other Tumor Promoting Pathways

By  

Current Pharmaceutical Design, Vol. 20, Iss. 17, 2014-05 ,pp. : 2912-2921

Bentham Science Publishers

Access to resources Recommend Favorite

Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer

By Buck Elizabeth   Mulvihill Mark  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 5, 2011-05 ,pp. : 605-621

Informa Healthcare

Access to resources Recommend Favorite

M1/M2 Macrophages in Diabetic Nephropathy: Nrf2/HO-1 as Therapeutic Targets

By  

Current Pharmaceutical Design, Vol. 24, Iss. 20, 2018-06 ,pp. : 2241-2249

Bentham Science Publishers

Access to resources Recommend Favorite